Conflicting results have recently been published about the benefits of combined T 4 and T 3 in treating hypothyroid patients. However, these studies may have been underpowered to detect differences in psychological well-being specifically related to T 4 replacement. We conducted a large, double-blind, randomized controlled trial of partial substitution of 50 g T 4 by 10 g T 3 vs. the original dose of T 4 in 697 hypothyroid patients. Thyroid function showed a rise in TSH (132%), a fall in free T 4 (35%, P < 0.001), and unchanged basal free T 3 levels (P ‫؍‬ 0.92). At 3 months, there was a large (39%) placebo effect improvement in psychiatric caseness defined by the General Health Questionnaire (GHQ) 12 score in the control group compared with baseline, and this was sustained at 12 months. 
A ROUND 1% OF THE population in iodine-sufficient countries receives T 4 replacement therapy, and over 5% have untreated subclinical hypothyroidism (1) (2) (3) . Although the thyroid gland produces T 4 and T 3 , standard thyroid hormone replacement comprises T 4 only, because it has a much longer half-life, yielding more stable serum levels with T 3 being generated from T 4 in the peripheral tissues. However, rodent data suggests that such replacement may not provide normal T 3 levels in all tissues (4, 5) .
Since the introduction of sensitive TSH assays in the 1980s, it has been recommended that thyroid hormone replacement with T 4 be titrated to achieve TSH levels in the laboratory reference range (6 -8) . For many individuals, this change resulted in a significant reduction in T 4 dose, and several studies indicate that titration to these levels results in high normal free T 4 but free T 3 levels in the low reference range (9 -11) . Anecdotally, many patients began to complain of impaired psychological well-being and symptoms suggestive of hypothyroidism when their dose was adjusted in this way (12) . Carr et al. (13) reported that patients preferred doses of T 4 50 g greater than the dose that achieved a normal TSH level. In an attempt to quantify this, we used the General Health Questionnaire (GHQ) in a cross-sectional study involving 1922 subjects (14) . A categorical score Ն 3 (maximum score, 12) on this scale indicates significant psychiatric morbidity (psychiatric caseness) and is predictive of similar outcome at complex psychiatric interview (15) . We identified a 6.7% absolute increase in psychiatric caseness in patients on T 4 with a TSH in the normal range compared with a matched control group (14) , although this was not apparent in a smaller study (16) . Such an increase, if true, could account for 150,000 excess psychiatric cases in the United States alone.
In 1999, a 5-wk crossover study of 33 patients suggested that substitution of 50 g T 4 with 12.5 g T 3 significantly improves mood although not cognitive function (17) , but more recently, five other trials have shown either no benefit (18 -21) or a worse outcome (22) . However, the differences in psychological wellbeing potentially attributable to T 4 replacement between patients and controls that we saw in our cross-sectional study, although important for the population as a whole, were relatively small and could have been missed in these studies. Here, we report a much larger and longer term study with greater power to resolve the issues raised by these studies.
Kingdom. Inclusion criteria were: age, 18 -75; T 4 dose Ն 100 g/d; TSH level recorded in the last 15 months and the last level known to be within the local laboratory reference range; and no T 4 dose adjustments in the last 3 months. Exclusion criteria were: a history of myocardial infarction, unstable angina or heart failure in the previous 3 months; thyroid cancer or secondary hypothyroidism; cholestyramine use; and use of antidepressants in the previous 3 months or amiodarone in the previous 12 months. The study was approved by the local research ethics committees.
Study protocol
The investigation was designed as a double-blind randomized controlled trial. Information about the study was sent to all the eligible patients with a stamped reply slip. On receiving the replies, interested patients were contacted by telephone to arrange appointments for the randomization visit. Patients were given opportunity to ask questions about the study, and then written, informed consent was obtained. They were then randomized by sequential allocation of study numbers (to which treatment groups had been randomly preallocated). Patients were given a trial pot, which either contained 10 g T 3 (T 3 group) or matched tablet of 50 g T 4 indistinguishable from the T 3 tablet (placebo/T 4 alone group). The remaining T 4 dose (original dose minus 50 g) was given in open-label packs. Patients were assessed at 3 months (visit 2) and 12 months (visit 3) and reminded before these visits to take their medication at the same time of day as their appointment time for 7 d before review.
Evaluations: physical and biochemical measurements
Detailed thyroid and other medical history was taken at visit 1. The following physical measurements were taken at each visit: weight, electrocardiogram, blood pressure (twice at 10-min intervals), resting pulse rate, and body composition (Bodystat1500, Bodystat, Ltd., Isle of Man, United Kingdom). A serum sample was taken at baseline (visit 1, not timed) and 24- 
Psychological measurements
At each visit, the patient's psychological well-being was assessed by the following scales: the GHQ-12 (15, 23, 24) , a disease-specific thyroid symptom questionnaire (TSQ) (14) , the Hospital Anxiety and Depression questionnaire (HADS) (25) , and 23 visual analog scales of mood, cognitive behavior, and physical symptoms used in the study of Bunevicius et al. (17) . In addition, patients completed a satisfaction question on a five-point scale and devised-questions on sleep and neuromuscular symptoms. The GHQ-12 and the TSQ were scored both by the Likert method (0 -3 per question, maximum score 36-most dissatisfied, linear method) and by the GHQ method (0, 0, 1, 1, maximum score 12-most dissatisfied) to assess caseness (using a threshold score of 3 or more, categorical method) (23, 24) . The changes in the GHQ-12 scores at 3 months, controlling for baseline scores, represented the primary outcomes.
Statistical methods
A sample size of 700 patients was calculated based on our crosssectional data to detect a 0.7-point difference between the groups on the GHQ-12 Likert scale with 80% power-a difference sufficient to correct the deficit seen in our cross-sectional study (14) . All the analyses were conducted in Stata version 8.0 (26) . Results were analyzed by intention to treat. The last observation was carried forward to replace missing values at 3 months follow-up due to withdrawal of the patients from the study. For linear and categorical variables, linear and logistic regression analyses, respectively, were used to detect the differences between the groups at 3 months adjusting for baseline values (age, sex, type of diagnosis, T 4 dose, duration of hypothyroidism, anti-TPO positivity, and baseline thyroid hormone measurements). Interactions between the baseline thyroid functions (free T 3 , free T 4 , TSH, and T 3 to T 4 ratio) and the treatment group were also investigated in the regression model for the two primary outcome variables (GHQ Likert and GHQ categorical scores). Repeated measures analysis by linear regression was used to detect any differences between the groups between 3 and 12 months follow-up. Median values were used as the summary statistic for TSH measurements because this parameter is not normally distributed, and statistical comparison was done using natural logarithmic values of TSH, yielding a comparison of geometric means.
Results
Twenty-eight family practices expressed interested in taking part in the study of the 37 contacted. Patients (n ϭ 3621) on T 4 identified from prescribing records were assessed for eligibility. Patients (n ϭ 1689) failed the inclusion and exclusion criteria on review of practice records, and a further 64 patients were considered inappropriate to take part by their general practitioners, mainly because of severe physical or mental disability. The remaining 1868 patients were contacted, 1460 replied, and 1014 showed interest in taking part in the study. On further chart review and telephone screening, 242 of these patients were excluded, mainly due to abnormal TSH or recent use of antidepressants. Of the patients, 772 finally attended the screening visit (visit 1). Sixty-eight patients did not fulfill all the inclusion and exclusion criteria. Seven patients changed their mind. The remaining 697 patients were randomized (Fig. 1, consort diagram) .
Baseline characteristics were similar between the two groups ( Table 1) . Eighty-one patients declined to continue with their study medication at or before visit 2 (36 in T 3 group), but follow-up data were obtained on 660 patients (94.7%). A further 41 patients declined to continue with study medication before visit 3 (25 on T 3 ), and a further 47 patients overall were lost to follow-up over this second period. Two patients (1 in each group) died of unrelated causes (hemorrhagic pancreatitis and subarachnoid hemorrhage). Reasons for patient withdrawals from study medication were obtained in 109 of 124 patients and considered to represent possible hyperthyroid symptoms (including headache, palpitations, tremors, nightmares, and difficulty in sleeping) in 27 patients (11 on T 3 ), hypothyroid symptoms (sluggish, increasing tiredness, sleepy, depressed, and weight gain) in 47 patients (30 on T 3 ), and a combination of both in six patients (three on T 3 ). The remaining withdrawals were due to adverse reaction (13), protocol violation (5), and unexplained withdrawal of consent (11) . Compliance with medication as assessed by returned tablet counts in those continuing with medication was good, both at 3 (T 3 , 96.7%; T 4 alone, 96.4%) and at 12 (T 3 , 97.4%; T 4 alone, 97.8%) months.
Thyroid function
Three months after intervention, the mean free T 4 in the T 3 group had fallen from the upper part to the lower part of the reference range and was significantly lower than in the T 4 alone group [1.07 vs. 1.52 ng/dl (13.73 vs. 19.59 pmol/liter), P Ͻ 0.001; Table 2 ]. Mean basal free T 3 levels were unchanged in both groups, but a 132% rise in median TSH was seen in the T 3 group (2.28 vs. 0.728 mIU/ml, P Ͻ 0.001 for ratio of geometric means; Table 2 ; Fig. 2, A-C) . In a pharmacokinetic substudy of 20 patients involved in the current study, basal levels were not different in the T 3 group, but free T 3 levels reached a peak 2-4 h after ingestion (40% higher than the baseline), and total 24-h exposure to T 3 represented by area under the curve was higher in the T 3 group (27) . Similar results over a 9-h period have recently been reported by Hennemann et al. (28) .
The relationship between TSH and free T 3 or free T 4 in patients on T 4 was investigated using the pooled baseline thyroid function test results in the two groups. Although both correlated well with log TSH, the gradient of the relationship was more marked with free T 4 than with free T 3 . The regression coefficients were log TSH vs. T 4 ϭ Ϫ0.53 [95% confidence interval (CI), Ϫ0.47, Ϫ 0.6; P Ͻ 0.001] and log TSH vs. T 3 ϭ Ϫ0.25 (95% CI, Ϫ0.17, Ϫ 0.32; P Ͻ 0.001; Fig. 3 ).
Psychological well-being and other outcomes
At 3 months, the GHQ scores by the Likert method improved markedly in both the placebo (T 4 alone) and the intervention (T 3 ) groups compared with baseline (baseline to 3 months, T 4 alone, 13.48 -11.13, P Ͻ 0.001; T 3 group, 13.42-10.67, P Ͻ 0.001) with a 39% relative improvement in psychiatric caseness in the placebo group (43.9 reducing to 26.6% caseness). These changes are consistent with a marked placebo effect, although improved compliance with medication in the placebo group as evidenced by a significant fall in the serum TSH levels (baseline to 3 months, T 4 alone, 0.94 -0.728 mIU/ml, P Ͻ 0.05) could have contributed ( Fig. 2; Table 2 ). Comparisons between the groups revealed a difference of 0.47 points in the GHQ scored by the Likert method, which was smaller, than the difference used to power the trial (0.7) and did not reach significance at the P Ͻ 0.05 level (95% CI, Ϫ0.26, ϩ1.12; P ϭ 0.218; Fig. 4 ). Using the categorical scoring methods with a threshold Ն 3, a significantly greater reduction in psychiatric caseness was seen in the T 3 group compared with T 4 alone [19.2 vs. 26.6%, odds ratio (OR), 0.61; 95% CI, 0.42, 0.90; P ϭ 0.01; Fig. 5 ; Table 2 ). Improvement was also seen in the HADS anxiety score at 3 months (OR, 0.55; 95% CI, 0.32, 0.95; P ϭ 0.033). However, no difference was seen in the TSQ scores, sleep, neuromuscular symptoms, HADS depression category, or visual analog scales, and the percentage of patients reporting that they felt better on direct questioning was not different (well-being question, Table  2 ). No significant differences were seen in any of the physical or biochemical measures other than a slightly lower diastolic blood pressure in the T 4 alone group ( Table 2) . The significance of these results was unchanged when controlled for age, sex, type of diagnosis, prestudy T 4 dose, use of other chronic medication, baseline GHQ scores, anti-TPO positivity, and baseline thyroid function (free T 3 , free T 4 , TSH, and T 3 to T 4 ratio).
Subgroup analyses
Predefined subgroup analysis demonstrated a significant interaction on GHQ scores between baseline free T 3 (as a continuous variable) and study group allocation (OR, 2.2; 95% CI, 1.28, 3.98; P ϭ 0.005). Division of free T 3 values into quartiles revealed that patients with baseline free T 3 in the highest quartile, approximately equivalent to the upper half of the reference range [Ͼ0.275 ng/dl (Ͼ4.27 pmol/liter), reference range, 0.18 -0.457 ng/dl (2.8 -7.1 pmol/liter)], responded best to the intervention (Table 3 ) (only one patient in the T 4 alone group, and none in the T 3 group had a free T 3 level above the normal range). No such effect was seen with baseline free T 4 or baseline values of TSH, T 3 to T 4 ratio, or GHQ scores.
Outcomes at 12 months
When the subjects were reassessed at 12 months, GHQ scores in the intervention group (T 3 ) had risen (worsened, P ϭ 0.0034), and there was now no difference between the two groups (T 3 vs. T 4 alone, P ϭ 0.24) ( Table 2 ; Fig. 4) . Interestingly, in both groups, the free T 3 to T 4 ratio fell significantly (T 3 group, 9% reduction; T 4 alone group, 6% reduction, both P Ͻ 0.001) (Fig. 2D) between months 3 and 12. This change was not explained by assay drift because samples from both visits were analyzed together. No change over this period was seen in TSH levels.
Discussion
Our results demonstrate a marked placebo effect but an equivocal benefit specifically attributable to the intervention from the partial T 3 substitution regime used. On the linear Likert scoring of the GHQ (primary outcome measure), the estimate of the benefit over and above the improvement seen in the control group (0.43 points) was less than the 0.7-point difference used to power the study (14) and was accompanied by a CI that included zero. Using the categorical scoring of the GHQ questionnaire to calculate psychiatric caseness, the estimated risk reduction attributable to the intervention was 0.61 with a CI that did not include zero (0.42, 0.90), and there was also a significant improvement in the HADS anxiety score (OR, 0.55; CI, 0.32, 0.95). However, no difference in psychological well-being was detected using the HADS depression score, visual analog scales of mood, cognitive behavior or physical symptoms, a satisfaction questionnaire, or our TSQ. In addition, the differences in GHQ caseness and HADS anxiety were not apparent after 12 months. Taken together, these results suggest that if there is a benefit from the intervention, it is easily overwhelmed by the size of the placebo effect and is insufficient to completely correct the difference between patients on T 4 and age-matched controls seen in the cross-sectional study used to power the trial.
Our protocol was designed to maximize sample size and contains several potential limitations. Firstly, the use of a fixed substitution of 50 g T 4 with 10 g T 3 resulted in a rise in TSH and a fall in T 4 to the low reference range in the intervention group indicating underreplacement with T 4 . Because tissues derive up to 50% of their intracellular T 3 directly from serum T 4 , this may have reduced the benefit gained in the intervention group and underlines the importance of replacing both T 3 and T 4 appropriately. Secondly, despite limiting study entry to patients on Ն100 g of T 4 (average daily dose 124.3 g), many of the subjects with primary hypothyroidism in the trial may have had residual thyroid function. This, in combination with the use of a fixed T 3 to T 4 substitution ratio, might be expected to result in further variability in achieving optimal final T 3 and T 4 levels in subjects after intervention. Thirdly, the timing of the baseline (visit 1) blood sample was not controlled, whereas the 3-and 12-month samples were taken 24 h postdosing with thyroid hormone. This may underlie the apparent fall in FT4 levels between baseline and 3 months in the T 4 group despite a fall in TSH because TSH levels are much less dependent on dose timing over the 24-h period (29) . Fourthly, as with previous studies, multiple psychological scales were used, increasing the possibility of positive findings by chance in one or more or the measures. However, primary and secondary analyses were defined in advance both in terms of the parameters to be analyzed and the primary outcome time point. For this reason, formal statistical correction was not made in reporting the results of the secondary analyses.
There have now been six other reported studies of the use of T 3 and T 4 in combination including the original report of Buneuvicius et al. (17) (18) (19) (20) (21) (22) . All used different T 4 reduction/T 3 substitution regimes, some using a crossover design and apart from the original report showed either no benefit (18 -21) or a worsening of well-being (22) even when a subgroup of dissatisfied patients was examined (22) . The major difference with the current report was in the number of participants. Calculations on the basis of the differences seen in our previous cross-sectional study resulted in the current study being over 6 times larger than any of the other studies (n ϭ 23-101). Even on this basis, we were somewhat optimistic in powering the study to detect only a difference equal to or greater than the whole difference between the groups in our cross-sectional study; indeed, the observed difference was that subjects with higher baseline free T 3 levels appear to benefit most is interesting in this respect, possibly suggestive of a threshold effect (Table 3 ), but further evidence using different baseline parameters is required.
The large size and long duration of the current study provide information on other aspects of thyroid hormone replacement. Early studies suggested that TSH levels are more sensitive to T 4 than T 3 levels (29) . Here, we confirm that this relationship holds true even with TSH levels in the laboratory reference range. Baseline thyroid function values showed a greater negative regression gradient between T 4 and TSH than between T 3 and TSH (Fig. 3) . In addition, TSH levels rose in response to a fall in T 4 levels in the intervention group, even in the face of unchanged or probably higher T 3 levels. This sensitivity of the pituitary/hypothalamic feedback to serum T 4 and T 3 explains how replacement with T 4 alone can frequently achieve normal TSH levels with a combination of low T 3 and high T 4 levels as observed previously in smaller studies (9 -11) and as seen in this study (Table 1 ). In addition, over a 9-month period, a significant fall in the T 3 to T 4 ratio was seen with no associated change in TSH (Fig. 4) . This may reflect slow adaptation of tissue deiodinases to changes in thyroid hormone levels (T 3 exposure in the intervention group and improved compliance in the T 4 group) as reported in in vitro studies (30) . Finally, the benefit attributed to placebo was larger (17.3% absolute reduction/39% relative reduction in psychiatric caseness; Table 2 ; Fig. 5 ) and more consistently maintained (no reduction after 12 months; Fig. 4 ) than expected. Indeed, the estimate of the benefit specifically attributable to the intervention (7.4% less psychiatric caseness) was over 2-fold smaller than this effect, suggesting that in clinical practice, much of the improvement with T 3 may reflect placebo benefit and that demonstrating a specific effect is difficult even in large clinical trials.
In conclusion, data from this large community-based study do not provide conclusive evidence of specific benefit from partial substitution of T 4 by T 3 in patients on T 4 replacement. However, they do underline the large size and sustained nature of the placebo effect that may be obtained in studies of this nature. It remains possible that a small subgroup of individuals does benefit specifically from partial substitution, but parameters identifying such a group have yet to be clearly identified. 
